Seoul, Korea – To address the growing global demand for clinical services, Thermo Fisher Scientific, the world leader in serving science, today announced the official opening of its new state-of-the-art GMP standard facility in South Korea. Strategically located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies − from cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management. A supportive government, modern infrastructure and an easily accessible patient population are helping this Asian nation become a top location for clinical trial research. Over the past few years, clinical trials have consistently grown in Korea, and with an increased number of core clinical trial sites certified by the Ministry of Food and Drug Safety (MFDS), formerly known as the KFDA, Korea boasts the second highest number of approved clinical trial sites globally, making it a leading emerging nation for clinical trial research in Asia. In addition, Korean R&D pharmaceutical companies have demonstrated a strong passion for innovative drug development resulting in a robust industry contributing to therapeutic healthcare developments at local and global levels. “Asia Pacific continues to be our fastest-growing market and a central contributor to our growth,” said Leon Wyszkowski, Thermo Fisher’s vice president of clinical services for North America and facility network. “In September 2015 we opened a new facility in Singapore to serve as a central hub for our Asia Pacific region, which compliments our clinical services facilities in Beijing and Suzhou, China; Tokyo, Japan and Ahmedabad, India. The opening of this new facility in South Korea is testament to our commitment to continue investing in the region as we build on the expertise of our local teams to strengthen our regional and global presence in the clinical supplies industry.“ About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.